![We Care for Every Heartbeat]({"type":"image" , "src" : "/sda/112416/JournalAd-TACD-Daiichi.jpg"})
References
- Bornstein AB, Rao SS, Marwaha K. Left ventricular hypertrophy. In Treasure Island (FL): StatPearls; 2022.
- Massera D, McClelland RL, Ambale-Venkatesh B, et al. Prevalence of unexplained left ventricular hypertrophy by cardiac magnetic resonance imaging in MESA. J Am Heart Assoc. 2019;8(8):e012250.
- Kis M, Dogan Y, Yildirim A, et al. Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR). Acta Cardiol. 2022;2022:1–10.
- Ternacle J, Krapf L, Mohty D, et al. Aortic stenosis and cardiac amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2019;74(21):2638–2651.
- Fe L, Rasmus R, Pernille LB, et al. Association of carpal tunnel syndrome with amyloidosis, heart failure, and adverse cardiovascular outcomes. J Am Coll Cardiol. 2019;74(1):15–23.
- Gillmore JD, Wechalekar A, Bird J, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol. 2015;168(2):207–218.
- Pieroni M, Chimenti C, Ricci R, et al. Early detection of fabry cardiomyopathy by tissue doppler imaging. Circulation. 2003;107(15):1978–1984.
- Nagueh SF. Anderson-Fabry disease and other lysosomal storage disorders. Circulation. 2014;130(13):1081–1090.
![Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.]({"type":"image" , "src" : "/sda/112387/JournalAd-TACD-BOEHR-MPU.jpg"})
![A bold vision to stop cardiovascular disease from being a leading cause of death.]({"type":"image" , "src" : "/sda/112402/JournalAd-amarin.jpg"})